Inside WoundScribe's Reapplication Tracking for Skin Substitutes

Skin substitutes and cellular tissue products live and die by reapplication. A single application rarely closes a chronic wound; the clinical and commercial story is in the repeat use. WoundScribe's Product Catalog is built to capture that story.

Why reapplication data is hard to get

Outside WoundScribe, reapplication signal is fragmented:

• Claims data lags months and is often incomplete for CTPs.
• Rep-reported use is anecdotal.
• EMR fields are inconsistent across sites.

Product teams end up guessing at real-world application counts, denial patterns, and drop-off after application two or three.

What WoundScribe tracks

Because every wound encounter runs through the AI-powered EMR for wound care, reapplications are captured structurally:

• Application number — first, second, third, and beyond, tied to the same wound.
• Interval between applications — matched against protocol windows.
• Trajectory response — did the wound improve, stall, or decline after each application, using serial measurements from AI-powered wound imaging.
• Billing code alignment — HCPCS units billed vs. applied, flagged for denial risk. Related: WISER: fixing wound care claim denials.

What product teams see

Aggregate, privacy-preserving reporting includes:

• Average applications per wound episode.
• Drop-off curve after application two.
• Trajectory response by application number.
• Denial rate by code and site.

Why it matters commercially

Reapplication data tells you where your product is being under-used (missed protocol windows), where it's being over-used (denial risk), and where trajectory response justifies continued application. That's actionable intelligence for medical affairs, market access, and sales.

See where reapplication tracking sits in the solutions overview.